ArticleJournal of nanobiotechnology2024
Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system.
Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Cancer Vaccine Development: Toward Artificial Intelligence-Assisted Personalized Cell Membrane Nanovaccine.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- From Antibiotic Resistance to Bacterial Vaccines: A New Approach to Controlling Resistant Bacterial Infections.Infection and drug resistance · 2026Review
- Outer membrane vesicles as a versatile nanoplatform for advanced vaccine development and immunotherapy.Frontiers in immunology · 2026Review
- Bioengineering modification and application of bacterial outer membrane vesicles.International journal of medical sciences · 2026Review
- Engineered Low-Endotoxin Bacterial Biomimetic Vesicles for Enhanced Oral Dual-Antigen Subunit Vaccine Delivery.Journal of extracellular vesicles · 2025Article
- Attenuated innate immunity in embryonic stem cells: mechanisms and therapeutic applications.Cell & bioscience · 2025Review
- Engineered Genetic Circuits Activated by Bezafibrate Improve ESC-Based TAA Cancer Vaccine Efficacy and PD-L1 Nanobody Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- NDM-5-carried outer membrane vesicles impair the efficacy of antibiotics against bacterial infections.Antimicrobial agents and chemotherapy · 2025Article
- Salmonella Typhimurium derived OMV nanoparticle displaying mixed heterologous O-antigens confers immunogenicity and protection against STEC infections in mice.Microbial cell factories · 2025Article
- Article
- Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy.Molecular cancer · 2024Review
- Recent advances in bacterial outer membrane vesicles: Effects on the immune system, mechanisms and their usage for tumor treatment.Journal of pharmaceutical analysis · 2024Review
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Embryonic stem cell (ESC)-derived epitopes can act as therapeutic tumor vaccines against different types of tumors Jin (Adv Healthc Mater 2023). However, these epitopes have poor immunogenicity and stimulate insufficient CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.